BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ErepoXen: Phase IIa data

An open-label, Indian Phase IIa trial in 30 CKD patients not on dialysis showed that single subcutaneous injections of 0.5, 1 and 2 µg/kg ErepoXen dose-dependently increased reticulocyte counts that were maintained...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >